New Questions About Generic Drugs

An Indian scientist works inside a laboratory of the Research and Development Centre of Natco Pharma Ltd. in Hyderabad, India, Tuesday, March 13, 2012. India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable. In a decision likely to upset Western pharmaceuticals, the patent office approved Natco Pharma Ltd.'s application to produce the kidney and liver cancer treatment sorefinib.  - (AP Photo/Mahesh Kumar A.)

An Indian scientist works inside a laboratory of the Research and Development Centre of Natco Pharma Ltd. in Hyderabad, India, Tuesday, March 13, 2012. India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable. In a decision likely to upset Western pharmaceuticals, the patent office approved Natco Pharma Ltd.'s application to produce the kidney and liver cancer treatment sorefinib.

(AP Photo/Mahesh Kumar A.)

New Questions About Generic Drugs

Generic drugs account for 80 percent of the pharmaceuticals prescribed to Americans. Why they’re cheaper and who’s responsible when something goes wrong.

Generic drugs account for 80 percent of the pharmaceuticals prescribed to Americans. Why they’re cheaper and who’s responsible when something goes wrong.

Guests

Ralph Neas

president and ceo, Generic Pharmaceutical Association

Katie Thomas

reporter, New York Times

Dr. Sidney Wolfe

director of the Health Research Group at Public Citizen; editor of WorstPills.org

Steven Brill

journalist and author of "Bitter Pill: How outrageous pricing and egregious profits are destroying our health care," a special report for Time Magazine's March 4, 2013, edition.

Please familiarize yourself with our Code of Conduct and Terms of Use before posting your comments.

Our address has changed!

The Diane Rehm Show is produced by member-supported WAMU 88.5 in Washington DC.